Northland Capital Markets analyst Suraj Kalia is sticking with her Outperform rating and $105 price target on Edwards Lifesciences (NYSE ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE